Submitted by Aelson Maciera (aelsoncm@terra.com.br) on 2017-10-06T18:08:45Z No. of bitstreams: 1 DissACP.pdf: 6605106 bytes, checksum: c63dcdec106579e271edaa4dc5a8bdcf (MD5) / Approved for entry into archive by Ronildo Prado (bco.producao.intelectual@gmail.com) on 2017-11-28T12:14:39Z (GMT) No. of bitstreams: 1 DissACP.pdf: 6605106 bytes, checksum: c63dcdec106579e271edaa4dc5a8bdcf (MD5) / Approved for entry into archive by Ronildo Prado (bco.producao.intelectual@gmail.com) on 2017-11-28T12:14:55Z (GMT) No. of bitstreams: 1 DissACP.pdf: 6605106 bytes, checksum: c63dcdec106579e271edaa4dc5a8bdcf (MD5) / Made available in DSpace on 2017-11-28T12:26:25Z (GMT). No. of bitstreams: 1 DissACP.pdf: 6605106 bytes, checksum: c63dcdec106579e271edaa4dc5a8bdcf (MD5) Previous issue date: 2017-02-24 / Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) / Nowadays, cancer is one of the most feared diseases, affecting each day more and more people worldwide. The importance of new cancer treatment researches is very clear since the ones that has been used are not very effective and may lead to drug resistance, implying in a constant dose increasing which can lead to toxicity issues. Collateral effects and the instability generated in the patient’s organism are also reasons why the necessity of discovering new cancer treatments is imminent. A treatment alternative that has aroused interest is the use of monoclonal antibodies as immunotherapics, since they act by stimulating the patient’s immune system neutralizing the tumor cells in a very efficient and specific way. This kind of antibody can be produced by culturing hybrid animal cells, better known as hybridoma, under strictly controlled conditions so they can be studied and used in human beings. For this reason, the major goal of this project was the production of murine monoclonal antibodies using hybridoma cell culture in order to stablish an efficient culture methodology for hybridomas PC-61 or DTA1 producers of monoclonal antibodies anti-CD25 and anti-GITR, respectively, with high quality and enough amounts using Fetal Bovine Serum (FBS) free medium to, in the future, carry out animal model studies of their potential as therapeutic agents for cancer treatment. Both hybridomas were cultivated on a small scale with RPMI medium and addition of SFB, for comparative purposes and only one was selcted for the second step. The sequential adaptation methodology test, consisted in a gradual percent’s reduction of medium with serum at the same time that increase the percentage of commercial medium without serum, and was selected the medium without SFB in which the hybridoma was better adapted. After was carried out on a laboratory scale in a system type spinner flask (500 ml) with the commercial medium selected in the previous step, in controlled conditions of temperature (37 ° C) and pH (7.2). Based on analyzes of cell culture results, amino acid consumption and monoclonal antibodies quantification , SFM commercial medium SFB-free provided better results for culturing the PC-61 hybridoma, allowing the pilot scale culture reached even higher cell densities than in the standard medium with addition of FBS. / O câncer é uma das doenças mais temidas da atualidade, e atinge cada vez mais pessoas em todo o mundo. A importância de pesquisas sobre novos tratamentos na luta contra o câncer é clara e consensual, uma vez que os que vem sendo utilizados, não são muito eficientes, causam resistência à medicação utilizada o que implica na utilização de doses crescentes que por sua vez podem gerar problemas de toxicidade. Os efeitos colaterais e a instabilidade gerada no organismo do paciente, também são fatores da necessidade de pesquisar novos caminhos para o tratamento do câncer. Uma das alternativas de tratamento que tem despertado interesse é a utilização de anticorpos monoclonais (mAbs) como imunoterápicos, os quais agem estimulando o próprio sistema imune do paciente neutralizando a ação das células tumorais de forma eficiente e específica. A produção de tais anticorpos pode ser feita mediante o cultivo de células animais híbridas, mais conhecidas como hibridomas, sobre condições estritamente controladas para que possam ser estudados e utilizados em humanos. Por essa razão definiu-se como objetivo desse trabalho a produção anticorpos monoclonais murinos por meio de cultivo de hibridomas com a finalidade de estabelecer uma metodologia eficiente de cultivo dos hibridomas PC-61 ou DTA1 secretores dos mAbs anti-CD25 e antiGITR respectivamente, com qualidade e em quantidades suficientes utilizando meios livres de soro fetal bovino (SFB), para a seguir efetuar estudos em modelo animal de seu potencial como agentes terapêuticos no tratamento de câncer. Os dois hibridomas foram cultivados em pequena escala utilizando meio RPMI-1640 e adição de SFB, para fins comparativos e somente um foi selecionado para a próxima etapa. O teste da metodologia de adaptação sequencial, onde houve a redução gradativa da porcentagem de meio RPMI-1640 com 10% de SFB e o aumento da porcentagem de meio comercial sem SFB, e foi selecionado o meio livre de SFB em que o hibridoma melhor se adaptou. Posteriormente foi realizado o cultivo do hibridoma em escala laboratorial em sistema de frasco agitado biorreator do tipo Spinner (500 mL) com o meio livre de SFB selecionado na etapa anterior, sob condições bem controladas de temperatura (37ºC), pH (7,2). Com base nas análises dos resultados dos cultivos celulares, metabolismo de aminoácidos e quantificação de mAbs, o meio comercial SFM livre de SFB proporcionou melhor resultados para o cultivo do hibridoma PC-61, permitindo que o cultivo em escala laboratorial atingisse densidades celulares ainda maiores que no meio padrão com adição de SFB. Como consequência desse vasto crescimento celular em quantidades abundantes de mAbs foram conseguidas para iniciar num futuro próximo ensaios em modelos animais.

Made available in DSpace on 2014-08-20T13:32:47Z (GMT). No. of bitstreams: 1 dissertacao_neida_lucia_conrad.pdf: 1248896 bytes, checksum: effbf3a6777d64f323ea5206861ef2dd (MD5) Previous issue date: 2013-03-12 / The infectious bronchitis (IB) is an acute and highly contagious disease caused by a coronavirus that infects mainly cells of the respiratory and genitourinary of chicken. The economic importance of this disease results from decreased production, such as internal and external quality of eggs, reduced hatchability, feed efficiency and weight gain, increased mortality, condemnation of carcasses at slaughter, and also with drugs spending to suppress secondary bacterial infections. The diagnosis of IB is based on virus isolation, together with serology. The use of monoclonal antibodies (MAbs) has been collaborated to diagnosis of this type of disease, but their use are still limited because the MAbs used are imported, increasing the cost of such methodologies. This work reports the production, characterization and application of MAbs against the virus of infectious bronchitis (IBV). For the production of MAbs, Balb/c mice were immunized intraperitoneally with classic IBV (M41) or variant IBV. We generated two hybridomas secreting MAbs anti-IBV (IgM isotype) from the fusion of B-lymphocytes from a mouse immunized with the variant IBV and myeloma cells. Following the characterization by ELISA and Western blot, it was observed that MAbs recognize the IBV classic and variant, showing more intense reactions with IBV variant. The AcM 2 G4 seems to be specific for protein S1. The applicability of the MAbs was assessed using the immunohistochemistry technique on histological tissues of birds inoculated experimentally with classic IBV. These MAbs anti-IBV had the same pattern of label of the MAb used as positive control, labeling predominantly inflammatory cells. This result can be explained by the fact that in severe cases of infection with IBV, the antigen may be located also in inflammatory cells. It was concluded that the MAbs obtained have potential for use in immunodiagnostic for IB. / A bronquite infecciosa das galinhas (BI) é uma doença aguda, altamente contagiosa, causada por um Coronavírus que infecta principalmente células dos aparelhos respiratório e genito-urinário das galinhas. A importância econômica dessa doença decorre da diminuição na produção e qualidade interna e externa dos ovos, da redução da eclodibilidade, da diminuição da eficiência alimentar e do ganho de peso e do aumento da mortalidade e da condenação de carcaças ao abate, além dos gastos com medicamentos para debelar infecções bacterianas secundárias. A confirmação do diagnóstico de BI é baseada no isolamento viral, em conjunto com a sorologia. O uso de anticorpos monoclonais (AcMs) tem colaborado e facilitado o diagnóstico desse tipo de enfermidade, porém seu uso ainda é limitado, pois os AcMs utilizados são importados, elevando o custo de tais metodologias. Este trabalho relata a produção, caracterização e aplicação de AcMs contra o vírus da bronquite infecciosa das galinhas (VBI). Para a produção dos AcMs, camundongos Balb/c foram imunizados intraperitonealmente com o VBI clássico (M41) local ou com o variante. Foram gerados dois hibridomas secretores de AcMs anti-VBI do isotipo IgM a partir da fusão entre os linfócitos B de um camundongo imunizado com o VBI variante e células de mieloma. Foi observado, na caracterização por ELISA indireto e Western blot, que os AcMs reconhecem o VBI clássico e variante, sendo as reações com o VBI variante mais intensas. O AcM 2G4 parece ser específico para a proteína S1. A aplicabilidade dos AcMs foi avaliada através da técnica de imuno-histoquímica em tecidos de aves inoculadas experimentalmente com o VBI clássico. Os AcMs anti-VBI apresentaram o mesmo padrão de marcação que o AcM utilizado como controle positivo, ou seja, marcaram predominantemente células inflamatórias. Este resultado pode ser explicado pelo fato de que, em casos mais severos da infecção por VBI, o antígeno pode ser localizado também em células inflamatórias. Concluiu-se que os AcMs obtidos apresentam potencial para uso no imunodiagnóstico para BI.

Monoclonal antibodies (MAbs) have an expanding market for use in diagnostic and therapeutic applications. Industrial production of these biopharmaceuticals is usually achieved based on fed-batch cultures of mammalian cells in bioreactors (Chinese hamster ovary (CHO) and Hybridoma cells), which can express different kinds of recombinant proteins. In order to reach high cell densities in these bioreactors, it is necessary to carry out an optimization of their production processes. Hence, macroscopic model equations must be developed to describe cell growth, nutrient consumption and product generation. These models will be very useful for designing the bioprocess, for developing robust controllers and for optimizing its productivity.<p>This thesis presents a new kinetic model of hybridoma cell metabolism in fed batch culture and typical illustration of a systematic methodology for mathematical modelling, parameter estimation and model-based optimization and state estimation of bioprocesses. <p>In the first part, a macroscopic model that takes into account phenomena of overflow metabolism within glycolysis and glutaminolysis is proposed to simulate hybridoma HB-58 cell cultures. The model of central carbon metabolism is reduced to a set of macroscopic reactions. The macroscopic model describes three metabolism states: respiratory metabolism, overflow metabolism and critical metabolism. The model parameters and confidence intervals are obtained via a nonlinear least squares identification. It is validated with experimental data of fed-batch hybridoma cultures and successfully predicts the dynamics of cell growth and death, substrate consumption (glutamine and glucose) and metabolites production (lactate and ammonia). Based on a sensitivity analysis of the model outputs with respect to the parameters, a model reduction is proposed. <p>In the next step, the effort is directed to the maximization of biomass productivity in fed-batch cultures of hybridoma cells based on the overflow metabolism model. Optimal feeding rate, on the one hand, for a single feed stream containing both glucose and glutamine and, on the other hand, for two separate feed streams of glucose and glutamine are determined using a Nelder-Mead simplex optimization algorithm. Two different objective functions (performance criteria) are considered for optimization; the first criterion to be maximized is the biomass productivity obtained at the end of the fed-batch culture, the second criterion to be minimized is the difference between global substrate consumption and the maximum respiratory capacity.<p>The optimal multi exponential feed rate trajectory improves the biomass productivity by 10% as compared to the optimal single exponential feed rate. Moreover, this result is validated by the one obtained with the analytical approach in which glucose and glutamine are fed to the culture so as to control the hybridoma cells at the critical metabolism state, which allows maximizing the biomass productivity. The robustness analysis of optimal feeding profiles obtained with different optimization strategies is considered, first, with respect to parameter uncertainties and, finally, with respect to model structure errors.<p>Finally, the overflow metabolism model is used to develop an extended Kalman filter for online estimation of glucose and glutamine in hybridoma cell fed-batch cultures based on the considered available measurements (biomasses (on-line), lactate and ammonia (on-line or off-line)). The observability conditions are examined, and the performances are analysed with simulations of hybridoma cell fed-batch cultures. Glutamine estimation sensitivity is enforced by minimizing a cost function combining a usual least-squares criterion with a state estimation sensitivity criterion. <p> / Doctorat en Sciences de l'ingénieur / info:eu-repo/semantics/nonPublished

No description available.

No description available.

Invariant natural killer T (iNKT) cells are a versatile subclass of T lymphocytes which recognize glycolipid antigens. iNKT cells are capable of rapidly producing a broad array of cytokines in response to stimulation; thus, they play an important role in the early regulation of a variety of immune responses. It was hypothesized that iNKT cells express functional Toll-like receptors (TLRs) and that stimulation of TLRs by their ligands modulates iNKT cells responses. In the first objective, it was revealed that upon stimulation with anti-CD3 monoclonal antibody and interferon (IFN)-α, expression of TLRs was enhanced in iNKT cells. Furthermore, stimulation of iNKT cells with TLR ligands led to a significant increase in the expression of several cytokines. In the second objective, the mechanisms behind the modulatory effects of the TLR9 ligand (CpG-ODN) on iNKT cells were determined. Altogether, these findings suggest a direct role for TLRs in iNKT cell activation. / Ontario Graduate Scholarship

Étant donné l'immunogénicité de l’antigène Dal et sa prévalence élevée (> 98% des chiens sont Dal-positifs), il peut être extrêmement difficile de trouver du sang compatible pour un patient Dal-négatif précédemment transfusé et ayant besoin d’une deuxième transfusion sanguine. De plus, l’accès aux réactifs pour le typage sanguin est actuellement limité, notamment parce qu'il dépend d’anticorps polyclonaux (AcP) produits à la suite de la sensibilisation de trois rares chiens Dal-négatifs identifiés sporadiquement au cours de la dernière décennie dans la colonie d'enseignement de la Faculté de médecine vétérinaire de l'Université de Montréal. Par conséquent, l’objective de cette étude était de produire et de caractériser un anticorps monoclonal murin (AcM) dirigé contre l’antigène canin Dal afin d’assurer la pérennité du typage sanguin Dal. Utilisant la technologie conventionnelle des hybridomes, 5 souris femelles BALB/c ont été immunisées par des injections intrapéritonéales répétées avec des concentrés de globules rouges canines lavés (GRc) Dal-positifs jusqu'à ce que le titrage d’anticorps soit suffisant (> 1 : 10000). Après la fusion de cellules spléniques avec des cellules de myélome, 573 surnageants ont été récoltés à partir du jour 12 post-fusion pour le dépistage avec la technique d'agglutination sur colonne de gel utilisant des GRc Dal-négatif et Dal-positif connus. Parmi 15 surnageants qui ont montré une réaction d’agglutination, un seul avait le patron souhaité (c'est-à-dire anti-Dal). Afin d’évaluer la spécificité et la sensibilité de l’AcM, le typage sanguin Dal de 62 échantillons de GRc a été réalisé en utilisant le AcM anti-Dal et deux AcP canins préalablement caractérisés: 45 échantillons Dal-positifs et 17 Dal-négatifs ont été identifiés avec une concordance de 100 % entre les réactifs (kappa = 1). L’AcM anti-Dal produit a été déterminé comme étant une IgG1. / Given the immunogenicity of the Dal antigen and its high prevalence (>98% of dogs are Dal-positive), it can be extremely difficult to find compatible blood for a previously transfused Dal-negative patient in need of a second blood transfusion. Moreover, access to blood typing reagents is currently limited, in part because it relies on polyclonal antibodies (PAb) produced following the sensitization of three rare Dal-negative dogs identified sporadically over the last decade in the teaching colony of the Faculty of Veterinary Medicine of the University of Montreal. Therefore, the objective of this study was to produce and characterize a murine monoclonal antibody (MAb) directed against the canine Dal antigen, to ensure perennity for Dal blood typing. Using conventional hybridoma technology, 5 BALB/c female mice were immunized by repeated intraperitoneal injections with Dal-positive washed canine red blood cell (cRBC) concentrates until antibody titer was sufficient (>1 : 10000). After fusion of splenic cells with myeloma cells, 573 supernatants were collected starting 12 days post-fusion for screening with the gel column agglutination technique using known Dal-negative and Dal-positive cRBC. Among 15 supernatants that showed an agglutination reaction, only one had the desired pattern (i.e., anti-Dal). To assess the specificity and sensitivity of the MAb, the Dal blood typing of 62 cRBC samples was performed using the anti-Dal MAb and two previously characterized canine PAb: 45 Dal-positive and 17 Dal-negative samples were identified with 100% agreement between reagents (kappa = 1). The anti-Dal MAb produced was determined to be IgG1.

Koffein (1,3,7-Trimethylxanthin) und Coprostanol (5beta-cholestan-3beta-ol) wurden im Berliner Oberflächenwasser nachgewiesen. Ihre Konzentrationen korrelierten mit dem Verunreinigungsgrad der Proben, was nahelegt, dass sie sich als Marker für menschliche Aktivität eignen. Bemerkenswerterweise wurde Koffein in jeder einzelnen Oberflächenwasserprobe oberhalb der Bestimmungsgrenze von 0,025 µg/L gefunden. Um Oberflächenwasserproben in größeren Serien zu untersuchen, war die Entwicklung zweier neuer Methoden erforderlich: ein Immunoassay, basierend auf einem monoklonalen Antikörper für Koffein und eine dispersive flüssig-flüssig Mikroextraktionsmethode (DLLME), gefolgt von Flüssigkeitschromatographie gekoppelt mit Tandem-Massenspektrometrie (LC-MS/MS) für Coprostanol. Der entwickelte Koffein-Immunoassay zeigt die beste je erhaltene Nachweisgrenze für Koffein (0,001 µg/L), erlaubt Hochdurchsatz-Analysen und erfordert keine Probenvorbereitung. Der Assay wurde auch erfolgreich für die Messung von Koffein in Getränken, Haarwaschmitteln, Koffeintabletten und menschlichem Speichel angewendet. Antikörper gegen Coprostanol sind nicht kommerziell erhältlich. Eine neue Strategie Anti-Coprostanol-Antikörper zu generieren wurde erarbeitet, die eine analoge Verbindung – Isolithocholsäure (ILA) – als Hapten verwendet, mit der eine Gruppe von Mäusen immunisiert wurde. Ein polyklonales Anti-ILA-Serum wurde produziert, welches Coprostanol bindet, aber die niedrige Affinität erlaubte nicht den Aufbau eines Immunoassays, der die Messung von Umweltkonzentrationen des Anayten (im Bereich ng/L) zulässt. Spezifische Anti-ILA-Immunglobuline G wurden auch in den Faeces der Mäuse gefunden. Coprostanol wurde in den Wasserproben durch die Verwendung einer neuentwickelten LC-MS/MS-Methode unter APCI-Ionisation (atmospheric pressure chemical ionisation) gemessen. Konzentrationen oberhalb von 0,1 µg/L wurden nach Voranreicherung der Probe mittels DLLME bestimmt. / Caffeine (1,3,7-trimethylxanthine) and coprostanol (5beta-cholestan-3beta-ol) were detected in samples of Berlin’s surface water. Their concentrations correlated with the contamination status of the samples, suggesting their usefulness as markers of human activity. Remarkably, caffeine concentrations were always well above the limit of quantitation of 0.025 µg/L. In order to screen surface water samples in larger series, the development of two novel methods was required: a monoclonal antibody-based immunoassay for caffeine and a dispersive liquid-liquid microextraction (DLLME) method, followed by liquid chromatography tandem mass spectrometry (LC-MS/MS) for coprostanol. The caffeine immunoassay developed shows the best analytical limit of detection (LOD) obtained so far for caffeine (0.001 µg/L), allows high-throughput analysis, and does not require sample pre-treatment. The assay was also successfully employed to measure caffeine in beverages, shampoos, caffeine tab-lets, and human saliva. Antibodies to coprostanol are not commercially available. A new strategy to generate anti-coprostanol antibodies was elaborated using an analogous com-pound as hapten – isolithocholic acid (ILA) – and immunizing a group of mice. A polyclonal anti-ILA serum was produced, which binds coprostanol but the low affinity did not permit setting up an immunoassay to measure environmental concentrations of the analyte (in the range of ng/L). Specific anti-ILA immunoglobulin G were also found in the faeces of the immunized mice. Coprostanol was quantified in the water samples using a newly developed LC-MS/MS method using atmospheric pressure chemical ionisation (APCI). Concentrations above 0.1 µg/L were determined after sample preconcentration using DLLME. This extraction method also proved to be successful for enrichment of coprostanol-related compounds such as cholesterol, cholestanol, cholestanone, ergosterol, and stigmasterol.